idecabtagene vicleucel
2seventy bio,bms
great presentation by dr. hansen on real world #cart #idecel for #mm consortium data! 77% would have been ineligible for trial, similar safety and efficacy #ims2022 
Hematologic Oncology @ClevelandClinic Myeloma/BMT/CART/Apheresis | Assistant Prof @CleClinicLCM of @CWRUSOM